[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100648848":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":21,"centralContacts":25,"locations":31,"responsibleParty":52,"collaborators":20,"id":54,"slug":55,"hasResults":56,"nctId":57,"briefTitle":58,"officialTitle":59,"acronym":20,"eligibilityCriteria":60,"healthyVolunteers":56,"sex":61,"minAge":62,"maxAge":20,"enrollmentInfo":63,"targetDuration":20,"studyType":66,"phases":67,"briefSummary":69,"conditions":70,"keywords":20,"overallStatus":72,"whyStopped":20,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":82},{"fullName":5,"class":6},"Banner Health","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Semaglutide Preoperative Treatment","EXPERIMENTAL","Participants enrolled in this single-arm study will receive weekly subcutaneous semaglutide for 3 to 6 months prior to planned radical prostatectomy. Semaglutide will be administered according to the FDA-approved dosing regimen, with dose titration as tolerated. Treatment will be discontinued one week prior to surgery, after which participants will proceed with standard-of-care radical prostatectomy and postoperative follow-up.",[13],"Drug: Semaglutide 2.4 mg",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DRUG","Semaglutide 2.4 mg","Semaglutide will be administered as a weekly subcutaneous injection. The dose will be titrated according to the FDA-approved labeling, starting at 0.25 mg once weekly and increasing as tolerated to a target maintenance dose of up to 2.4 mg once weekly. Treatment will continue for 3 to 6 months prior to planned radical prostatectomy.",[9],null,[22],{"name":23,"affiliation":5,"role":24},"Issac Bowman","PRINCIPAL_INVESTIGATOR",[26],{"name":27,"role":28,"phone":29,"phoneExt":20,"email":30},"Nibu Mathew","CONTACT","480-256-3425","nibu.mathew@bannerhealth.com",[32],{"facility":33,"status":20,"city":34,"state":35,"zip":36,"country":37,"countryCode":38,"cosmosGeoPoint":39,"geoPoint":44,"contacts":45},"Banner MD Anderson Cancer Center at Gateway","Gilbert","Arizona","85234","United States","US",{"type":40,"coordinates":41},"Point",[42,43],-111.78903,33.35283,{"lat":43,"lon":42},[46,49],{"name":47,"role":28,"phone":48,"phoneExt":20,"email":30},"Clinical Trials Senior Manager","602-747-3647",{"name":50,"role":28,"phone":20,"phoneExt":20,"email":51},"Director, Clinical Trials","klarissa.jones@bannerhealth.com",{"type":53,"investigatorFullName":20,"investigatorTitle":20,"investigatorAffiliation":20,"oldNameTitle":20,"oldOrganization":20},"SPONSOR","100648848","early-phase-1-preoperative-semaglutide-prior-to-radical-prostatectomy-100648848",false,"NCT07727473","Preoperative Semaglutide Prior to Radical Prostatectomy","A Prospective, Open-label, Exploratory Interventional Trial of Preoperative Semaglutide Prior to Radical Prostatectomy for Intermediate-risk Localized Prostate Cancer","Inclusion Criteria:\n\n* Male participants aged ≥18 years\n* Biopsy-proven intermediate-risk localized prostate cancer per NCCN risk stratification criteria\n* Planning to undergo radical prostatectomy, and surgical delay of 3-6 months is deemed appropriate by the investigator\n* Body mass index (BMI) \\>35 kg\u002Fm²\n* No prior exposure to androgen deprivation therapy or androgen receptor pathway inhibitors\n\nExclusion Criteria:\n\n* Prostate cancer risk classification other than intermediate risk\n* Hemoglobin A1c (HbA1c) \\>9%\n* Personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN2)\n* Baseline gastroparesis, dysphagia, or other significant gastrointestinal disease limiting oral intake\n* Current or recent (within 12 months) exposure to GLP-1 receptor agonist therapy\n* Delay of radical prostatectomy by 3-6 months is not deemed advisable by the investigator","MALE","18 Years",{"count":64,"type":65},20,"ESTIMATED","INTERVENTIONAL",[68],"EARLY_PHASE1","In this exploratory, single-arm, nonrandomized trial, the impact of the preoperative utilization of the glucagon-like peptide-1 (GLP-1) receptor agonist (RA) semaglutide prior to radical prostatectomy in participants with intermediate risk prostate cancer will be investigated. Semaglutide will be administered according to the FDA-approved label for chronic weight management and participants will be dosed with a weekly subcutaneous injection. The primary aim of this trial is to explore the tumor biological activity of semaglutide in these participants. The trial will also evaluate the safety and tolerability of this preoperative treatment, along with the impact on physiologic\u002Fmetabolic parameters.",[71],"Prostate Cancer","NOT_YET_RECRUITING","2026-07-23",{"date":75,"type":76},"2026-07-27","ACTUAL",{"date":78,"type":65},"2026-07",{"date":80,"type":65},"2029-05",{"name":5,"class":6},1]